We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2I8 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects PTP1B. It targets an epitope within 15 amino acids from the C-terminal half.

KLH-conjugated linear peptide corresponding to 15 amino acids from the C-terminal half of human PTP1B.

Quality Control Testing

Evaluated by Western Blotting in SK-OV-3 cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected PTP1B in SK-OV-3 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected PTP1B in lysate from mouse brain tissue and COLO 320DM cells .

Flow Cytometry Analysis: 1 µg from a representative lot detected PTP1B in one million Ramos cells.

Affinity Binding Assay: A representative lot of this antibody bound PTP1B peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected PTP1B in human tonsil tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Tyrosine-protein phosphatase non-receptor type 1 (UniProt:P18031; also known as Protein-tyrosine phosphatase 1B, PTP-1B, EC:3.1.3.48) is encoded by the PTPN1 (also known as PTP1B) gene (Gene ID: 5770) in human. PTP1B is the prototypic member of the protein tyrosine phosphatase (PTP) family, which comprises at least 37 proteins. Members of the PTP family are characterized by a catalytic phosphatase domain and includes both transmembrane and cytosolic enzymes. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTP1B expression is ubiquitous, with particularly high levels in metabolic tissues such as the liver and adipose tissue. It is also expressed in keratinocytes. PTP1B is predominantly localized in the endoplasmic reticulum and cytoplasm. As a member of PTP family, PTP1B also has a conserved catalytic Tyrosine-protein phosphatase domain (aa 3-277). PTP1B is a negative regulator of insulin signaling by dephosphorylating the phosphotryosine residues of insulin receptor kinase. Insulin also influences the expression of splice variants of PTP1B. PTP1B is also reported to dephosphorylate epidermal growth factor receptor kinase, as well as JAK2 and TYK2 kinases, which implicated the role of this PTP in cell growth control, and cell response to interferon stimulation. Dysregulation of PTP1B has been implicated in several diseases, including type 2 diabetes, obesity, and certain cancers, making it a promising target for therapeutic intervention. Inhibitors of PTP1B are being explored as a potential treatments for these metabolic disorders. Recent studies suggest four main approaches aim to inhibit PTP1B: orthosteric, allosteric, bidentate inhibition, and PTPN1 gene silencing, though challenges remain to develop a potent PTP1B inhibitor. Due to high conservation among PTP family members, most PTP1B inhibitors lack specificity. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Coronell-Tovar, A., (2024). FEBS Lett. 598(15);1811-1838; Liu, R., et al. (2022). Int J Mol Sci. 23(13), 7027).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.